Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution.
It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles.
The company is headquartered in Salt Lake City, Utah.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | -0.09 Increased by +40.00% | -0.08 Decreased by -12.50% |
| Mar 13, 24 | -0.06 Decreased by -500.00% | -0.07 Increased by +14.29% |
| Nov 7, 23 | -0.02 Increased by +88.24% | -0.09 Increased by +77.78% |
| Aug 14, 23 | -0.29 Decreased by -314.29% | -0.12 Decreased by -141.67% |
| May 12, 23 | -0.15 Increased by +28.57% | -0.14 Decreased by -7.14% |
| Mar 13, 23 | -0.01 Decreased by -114.29% | -0.12 Increased by +91.67% |
| Nov 7, 22 | -0.17 Decreased by -140.48% | -0.22 Increased by +22.73% |
| Aug 15, 22 | -0.07 Increased by +66.67% | -0.20 Increased by +65.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 108.00 K Decreased by -37.93% | -2.42 M Increased by +80.06% | Decreased by -2.24 K% Increased by +67.88% |
| Jun 30, 23 | 269.00 K Increased by +668.57% | -25.14 M Decreased by -745.02% | Decreased by -9.35 K% Decreased by -183.92% |
| Mar 31, 23 | 107.00 K Increased by +256.67% | -13.87 M Increased by +1.48% | Decreased by -12.97 K% Increased by +72.38% |
| Dec 31, 22 | 234.00 K Increased by +17.59% | 8.62 M Increased by +94.78% | Increased by +3.68 K% Increased by +65.64% |
| Sep 30, 22 | 174.00 K Increased by +58.18% | -12.13 M Decreased by -141.90% | Decreased by -6.97 K% Decreased by -126.49% |
| Jun 30, 22 | 35.00 K Decreased by -82.59% | 3.90 M Increased by +216.32% | Increased by +11.14 K% Increased by +768.03% |
| Mar 31, 22 | 30.00 K Decreased by -85.92% | -14.08 M Increased by +64.58% | Decreased by -46.94 K% Decreased by -151.49% |
| Dec 31, 21 | 199.00 K Increased by +586.21% | 4.42 M Increased by +468.51% | Increased by +2.22 K% Decreased by -17.15% |